Viral infections and related fatal adverse events associated with complement inhibitors for PNH: a real-world pharmacovigilance analysis in FAERS

Complement inhibitors, particularly C3 agents, are associated with significant reporting of infectious AEs in FAERS, including specific viral infections like influenza and herpes. Early onset of viral AEs highlights the need for vigilance early in treatment. While advanced age and C5 use heighten mortality risk, the attenuated lethality of viral AEs suggests a distinct pathophysiological interplay warranting mechanistic study. The divergent risk profiles between C3 and C5 inhibitors underscore the need for personalized risk-benefit assessments in complement inhibition strategies.